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1. INTRODUCTION {#cam43147-sec-0005}
===============

Bladder cancer is one of the most common cancer types and is a significant cause of tumor‐related death worldwide.[^1^](#cam43147-bib-0001){ref-type="ref"} The worldwide age‐standardized incidence rate (per 100 000 person/y) of bladder cancer is 9.0 for men and 2.2 for women.[^2^](#cam43147-bib-0002){ref-type="ref"} The most common pathological type is transitional cell carcinoma (TCC),[^3^](#cam43147-bib-0003){ref-type="ref"} and thus, treatments for bladder cancer focus primarily on TCC. Since Amin et al reported a micropapillary component in TCC of the urinary bladder and its poor prognosis in 1994.[^4^](#cam43147-bib-0004){ref-type="ref"} The incidence of micropapillary urothelial carcinoma (MPUC) is 0.7%‐8.3%, according to various published articles.[^5^](#cam43147-bib-0005){ref-type="ref"}, [^6^](#cam43147-bib-0006){ref-type="ref"} Micropapillary urothelial carcinoma is characterized by small, tight clusters of high‐grade tumor cells that lack true fibrovascular cores and are contained within lacunar spaces; thus, it often has an aggressive clinical course.[^7^](#cam43147-bib-0007){ref-type="ref"} However, MPUC histology as an independent prognostic factor is still controversial. According to Sui et al\'s analysis of the National Cancer Database, MPUC has a poor prognosis regardless of treatment modality.[^8^](#cam43147-bib-0008){ref-type="ref"} However, the multi‐institutional analysis by Mitra et al found that even MPUC is associated with advanced disease at cystectomy, but the clinical outcomes are similar to those of pure TCC after controlling for pathologic features.[^9^](#cam43147-bib-0009){ref-type="ref"} Moreover, a meta‐analysis supports the finding that patients with MPUC who undergo radical cystectomy (RC) have survival outcomes similar to those of patients with TCC.[^10^](#cam43147-bib-0010){ref-type="ref"} Thus far, given MPUC\'s rarity, there is no analysis based on sufficient sample size. Therefore, we used the national Surveillance, Epidemiology, and End Results (SEER) database (2004‐2016) to investigate prognostic values of clinicopathological characteristics and survival outcomes in MPUC of the urinary bladder.

2. MATERIALS AND METHODS {#cam43147-sec-0006}
========================

2.1. Data resource and study population {#cam43147-sec-0007}
---------------------------------------

Adults patients (≥18 years of age) who were registered from 2004 to 2016 in the SEER database were selected. The primary cancer site was restricted to the urinary bladder according to the International Classification of Disease for Oncology, Third Edition. Patients were included only if the histology was MPUC or TCC. The diagnosis was confirmed by positive histology and was their first or only cancer diagnosis (first positive indicator of malignancy).

2.2. End points {#cam43147-sec-0008}
---------------

The main end points were overall mortality (OM) and cancer‐specific mortality (CSM) according to data in the SEER database. Overall mortality refers to deaths from any cause, while CSM is defined as death from MPUC or TCC according to the recorded cause of death. Survival time was the duration from initial diagnosis to death from any cause or to the last follow‐up.

2.3. Statistical analysis {#cam43147-sec-0009}
-------------------------

Baseline characteristics were assessed to determine whether there were significant differences in the distribution of the study population. Two‐sample *t* tests and Pearson\'s chi‐square tests were performed for continuous variables and categorical variables, respectively. Continuous variables were presented as the mean ± SD. For age at diagnosis and survival (in months), medians and interquartile ranges were also reported. Categorical variables were shown as frequencies and their proportions. The OM and CSM of each histological subtype were compared using unadjusted Kaplan‐Meier curves and the log‐rank test.

The multivariable Cox proportional hazard model was used to calculate hazard ratios (HR) and their 95% confidence intervals (95% CI) stratified by histological types. The following covariates were adjusted: sex, age at diagnosis, primary site, treatment modality (surgery and radiation), and tumor‐node‐metastasis (TNM) stage. Subgroup analyses were performed by multivariate regression analysis. Sex, age at diagnosis, TNM stage, and treatment modality (surgery and radiation) were adjusted in the Cox model. Tests to determine interactions were also used in the subgroup analyses. Propensity score matching (PSM) was used to further adjust the model for potential baseline confounding factors. All analyses were performed with the statistical software packages R ([http://www.R‐project.org](http://www.R-project.org); The R Foundation) and EmpowerStats (<http://www.empowerstats.com>; X&Y Solutions, Inc).

3. RESULTS {#cam43147-sec-0010}
==========

3.1. Baseline characteristics of the study population {#cam43147-sec-0011}
-----------------------------------------------------

In all, 154 972 patients were diagnosed with TCC and MPUC in the SEER database from 2004 to 2016. This study included 154 453 patients with TCC and 519 patients with MPUC were included. Table [1](#cam43147-tbl-0001){ref-type="table"} includes the patients\' baseline characteristics. At diagnosis, patients with MPUC were close in age to those with TCC (MPUC 71.16 ± 10.91 vs TCC 70.91 ± 12.06, *P* = .628). Most patients were males in both the MPUC (80.54%) and TCC (76.97%) groups, and there was no difference in the proportion of males and females between the two groups (*P* = .315). Patients in the MPUC group presented at a more advanced stage than those in the TCC group, as shown by a higher rate of muscle invasive disease (63.39% vs 9.39%, *P* \< .001), lymph node metastasis (24.28% vs 1.32%, *P* \< .001), and distal metastasis (10.79% vs 1.17%, *P* \< .001). Higher‐grade disease was also more common in the MPUC group (97.49% vs 49.38%, *P* \< .001). The surgery constituent ratio was significantly different between the two groups (*P* \< .001), and patients in the MPUC group were more likely to undergo RC (19.27% vs 2.68%) and pelvic exenteration (17.34% vs 1.56%). Moreover, lymph nodes were more likely to be removed from patients in the MPUC group than from patients in the TCC group (38.54% vs 4.24%, *P* \< .001). Moreover, regarding known radiation therapy, beam radiation was used more frequently in the MPUC group than in the TCC group (11.18% vs 2.00%, *P* \< .001).

###### 

Baseline demographic and clinicopathologic characteristics of patients with MPUC compared to TCC

                                     MPUC (n = 519)        TCC (n = 154 453)     *P*‐value
  ---------------------------------- --------------------- --------------------- -----------
  Mean age (y, SD)                   71.16 ± 10.91         70.91 ± 12.06         .628
  Median age (y, IQR)                71.00 (64.00‐79.00)   72.00 (63.00‐80.00)   .866
  Sex                                                                            .054
  Male                               418 (80.54%)          118 876 (76.97%)      
  Female                             101 (19.46%)          35 577 (23.03%)       
  Marital status                                                                 .065
  Married                            322 (62.04%)          92 245 (59.72%)       
  Single                             60 (11.56%)           15 571 (10.08%)       
  Widowed/Divorced                   108 (20.81%)          33 334 (21.58%)       
  Unknown                            29 (5.59%)            13 303 (8.61%)        
  Race                                                                           .164
  White                              462 (89.02%)          138 377 (89.59%)      
  Black                              30 (5.78%)            7584 (4.91%)          
  Other                              25 (4.82%)            6368 (4.12%)          
  Unknown                            2 (0.39%)             2124 (1.38%)          
  Year of diagnosis                                                              \<.001
  2004                               12 (2.31%)            11 581 (7.50%)        
  2005                               11 (2.12%)            11 076 (7.17%)        
  2006                               23 (4.43%)            11 365 (7.36%)        
  2007                               23 (4.43%)            11 745 (7.60%)        
  2008                               26 (5.01%)            11 643 (7.54%)        
  2009                               44 (8.48%)            11 632 (7.53%)        
  2010                               42 (8.09%)            11 919 (7.72%)        
  2011                               36 (6.94%)            11 794 (7.64%)        
  2012                               42 (8.09%)            12 299 (7.96%)        
  2013                               48 (9.25%)            12 157 (7.87%)        
  2014                               68 (13.10%)           12 341 (7.99%)        
  2015                               67 (12.91%)           12 534 (8.12%)        
  2016                               77 (14.84%)           12 367 (8.01%)        
  Primary site                                                                   \<.001
  Trigone of bladder                 27 (5.20%)            9944 (6.44%)          
  Dome of bladder                    27 (5.20%)            4541 (2.94%)          
  Lateral wall of bladder            97 (18.69%)           34 216 (22.15%)       
  Anterior wall of bladder           9 (1.73%)             2861 (1.85%)          
  Posterior wall of bladder          44 (8.48%)            14 551 (9.42%)        
  Bladder neck                       11 (2.12%)            4481 (2.90%)          
  Ureteric orifice                   5 (0.96%)             6986 (4.52%)          
  Urachus                            1 (0.19%)             25 (0.02%)            
  Overlapping lesion of bladder      85 (16.38%)           14 142 (9.16%)        
  Bladder, NOS                       213 (41.04%)          62 706 (40.60%)       
  T stage                                                                        \<.001
  Ta                                 18 (3.47%)            99 586 (64.48%)       
  Tis                                5 (0.96%)             2450 (1.59%)          
  T1                                 164 (31.60%)          36 159 (23.41%)       
  T2                                 195 (37.57%)          10 394 (6.73%)        
  T3                                 75 (14.45%)           2014 (1.30%)          
  T4                                 59 (11.37%)           2095 (1.36%)          
  Unknown                            3 (0.58%)             1755 (1.14%)          
  N stage                                                                        \<.001
  N0                                 384 (73.99%)          149 639 (96.88%)      
  N1                                 32 (6.17%)            992 (0.64%)           
  N2                                 86 (16.57%)           979 (0.63%)           
  N3                                 8 (1.54%)             72 (0.05%)            
  Unknown                            9 (1.73%)             2771 (1.79%)          
  M stage                                                                        \<.001
  M0                                 459 (88.44%)          150 922 (97.71%)      
  M1                                 56 (10.79%)           1810 (1.17%)          
  Unknown                            4 (0.77%)             1721 (1.11%)          
  Grade                                                                          \<.001
  Low                                9 (2.51%)             39 365 (50.62%)       
  High                               349 (97.49%)          38 407 (49.38%)       
  Surgery                                                                        \<.001
  No surgery                         17 (3.28%)            8192 (5.30%)          
  TURBT                              244 (47.01%)          111 962 (72.49%)      
  Partial cystectomy                 9 (1.73%)             1134 (0.73%)          
  Radical cystectomy                 100 (19.27%)          4143 (2.68%)          
  Pelvic exenteration                90 (17.34%)           2404 (1.56%)          
  Other                              58 (11.18%)           26 357 (17.06%)       
  Unknown procedure                  1 (0.19%)             261 (0.17%)           
  Lymph nodes removed                                                            \<.001
  None                               319 (61.46%)          147 899 (95.76%)      
  More than one                      200 (38.54%)          6554 (4.24%)          
  Radiation                                                                      \<.001
  Beam radiation                     58 (11.18%)           3094 (2.00%)          
  Radioactive implants               0 (0.00%)             12 (0.01%)            
  Combination of beam and implants   0 (0.00%)             2 (0.00%)             
  Radioisotopes                      0 (0.00%)             11 (0.01%)            
  Radiation unknown                  0 (0.00%)             68 (0.04%)            
  Performance unknown                461 (88.82%)          151 266 (97.94%)      
  Cancer‐specific mortality                                                      \<.001
  Alive                              373 (71.87%)          141 802 (91.81%)      
  Dead                               146 (28.13%)          12 651 (8.19%)        
  Overall mortality                                                              \<.001
  Alive                              268 (51.64%)          54 682 (35.40%)       
  Dead                               251 (48.36%)          99 771 (64.60%)       
  Survival time (y, SD)              31.76 (33.08)         54.94 (42.02)         \<.001
  Survival time (y, IQR)             19.00 (8.00‐44.00)    46.00 (19.00‐85.00)   \<.001

Abbreviations: IQR, interquartile range; MPUC, micropapillary urothelial carcinoma; NOS, not otherwise specified; TCC, transitional cell carcinoma; TURBT, transurethral resection of bladder tumor.
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3.2. Survival analyses {#cam43147-sec-0012}
----------------------

In survival analyses, the overall survival probability of patients in the MPUC group declined significantly faster than that of patients in the TCC group (*P* \< .0001; Figure [1](#cam43147-fig-0001){ref-type="fig"}). When the landmark was set at 5 years (60 months), the survival probability of the MPUC group also declined faster in the OM analyses (Figure [S1](#cam43147-sup-0001){ref-type="supplementary-material"}). The MPUC group also had a lower survival probability in the CSM analyses (*P* \< .0001; Figure [1](#cam43147-fig-0001){ref-type="fig"}).

![Cancer‐specific mortality and overall mortality of patients with micropapillary urothelial carcinoma (MPUC) and transitional cell carcinoma (TCC) respectively](CAM4-9-4897-g001){#cam43147-fig-0001}

Table [2](#cam43147-tbl-0002){ref-type="table"} presents multivariable Cox proportional hazard models. After adjustments for age, sex, TNM stage, tumor site, and treatment method, the adjusted model II showed that the MPUC group had a significantly higher risk of OM compared with the TCC group (HR = 1.39, 95% CI = 1.22‐1.57, *P* \< .0001), while no difference in CSM was observed between the two groups (HR = 1.18, 95% CI = 1.00‐1.40, *P* = .0505). To minimize selection bias, PSM was performed for baseline factors and treatments (Table [3](#cam43147-tbl-0003){ref-type="table"}). However, there were still differences in N stage, M stage, grade, surgery, and lymph nodes removed between the groups. Furthermore, we performed an extra adjustment to analyze the mismatched baseline factors. In the PSM adjusted model I, the MPUC group did not show a higher risk of OM (HR = 1.09, 95% CI = 0.92‐0.29, *P* = .3097) or CSM (HR = 1.18, 95% CI = 0.92‐1.51, *P* = .2049). After further adjustment for T stage and radiation, the PSM adjusted model II showed that the MPUC group faced higher risks of CSM (HR = 1.30, 95% CI = 1.00‐1.67, *P* = .0469), but there was no difference in OM (HR = 1.10, 95% CI = 0.93‐1.31, *P* = .2688).

###### 

Multivariable Cox proportional hazard model

  Outcomes                    MPUC HR (95% CI)    *P*‐value
  --------------------------- ------------------- -----------
  Overall mortality                               
  Non‐adjusted                1.50 (1.33, 1.70)   \<.0001
  Adjusted I                  1.40 (1.24, 1.59)   \<.0001
  Adjusted II                 1.39 (1.22, 1.57)   \<.0001
  PSM non‐adjusted            1.48 (1.29, 1.71)   \<.0001
  PSM adjusted                1.10 (0.93, 1.31)   .2688
  Cancer‐specific mortality                       
  Non‐adjusted                5.20 (4.42, 6.12)   \<.0001
  Adjusted I                  1.06 (0.90, 1.25)   .5044
  Adjusted II                 1.18 (1.00, 1.40)   .0505
  PSM non‐adjusted            1.35 (1.12, 1.62)   .0016
  PSM adjusted                1.30 (1.00, 1.67)   .0469

Adjusted I model adjust for: T stage; N stage; M stage.

Adjusted II model adjust for: Sex; Age; Primary Site; T stage; N stage; M stage; surgery; radiation.

PSM non‐adjusted model adjust for none.

PSM adjusted model adjust for: T stage; N stage; M stage; surgery; radiation; grade; lymph nodes removed.

Abbreviations: HR, hazard ratio; MPUC, micropapillary urothelial carcinoma; PSM, propensity score matching.
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###### 

Propensity score matching for baseline factors

                                  MPUC (n = 519)   TCC (n = 1996)   Standardized difference   *P*‐value
  ------------------------------- ---------------- ---------------- ------------------------- -----------
  Mean Age (y, SD)                71.06 ± 10.90    71.01 ± 11.40    0.0046                    .9280
  Sex                                                               0                         1.0000
  Male                            401 (80.4)       1604 (80.4)                                
  Female                          98 (19.6)        392 (19.6)                                 
  Marital status                                                                              .2326
  Married                         312 (62.5)       1149 (57.6)      0.1014                    
  Single                          58 (11.6)        247 (12.4)       0.0231                    
  Widowed/Divorced                101 (20.2)       470 (23.5)       0.0800                    
  Unknown                         28 (5.6)         130 (6.5)        0.0378                    
  Race                                                                                        .8007
  White                           442 (88.6)       1776 (89)        0.0127                    
  Black                           30 (6)           125 (6.3)        0.0104                    
  Other                           25 (5)           83 (4.2)         0.0407                    
  Unknown                         2 (0.4)          12 (0.6)         0.0284                    
  Primary site                                                                                .1086
  Trigone of bladder              26 (5.2)         89 (4.5)         0.0350                    
  Dome of bladder                 26 (5.2)         73 (3.7)         0.0755                    
  Lateral wall of bladder         96 (19.2)        347 (17.4)       0.0479                    
  Anterior wall of bladder        9 (1.8)          55 (2.8)         0.0638                    
  Posterior wall of bladder       42 (8.4)         153 (7.7)        0.0276                    
  Bladder neck                    11 (2.2)         63 (3.2)         0.059                     
  Ureteric orifice                5 (1)            51 (2.6)         0.1177                    
  Urachus                         1 (0.2)          1 (0.1)          0.0425                    
  Overlapping lesion of bladder   81 (16.2)        283 (14.2)       0.0572                    
  Bladder, NOS                    202 (40.5)       881 (44.1)       0.0741                    
  T stage                                                                                     .0931
  Ta                              18 (3.6)         72 (3.6)         0                         
  Tis                             4 (0.8)          16 (0.8)         0                         
  T1                              156 (31.3)       648 (32.5)       0.0258                    
  T2                              193 (38.7)       771 (38.6)       0.0010                    
  T3                              71 (14.2)        244 (12.2)       0.0592                    
  T4                              55 (11)          194 (9.7)        0.0427                    
  Unknown                         2 (0.4)          51 (2.6)         0.1792                    
  N stage                                                                                     \<.0001
  N0                              372 (74.5)       1535 (76.9)      0.0549                    
  N1                              29 (5.8)         116 (5.8)        0                         
  N2                              81 (16.2)        215 (10.8)       0.1603                    
  N3                              8 (1.6)          13 (0.7)         0.0903                    
  Unknown                         9 (1.8)          117 (5.9)        0.2126                    
  M stage                                                                                     .0269
  M0                              444 (89)         1788 (89.6)      0.0194                    
  M1                              51 (10.2)        160 (8)          0.0766                    
  Unknown                         4 (0.8)          48 (2.4)         0.1279                    
  Grade                                                             0.3848                    \<.0001
  Low                             6 (1.7)          112 (11)                                   
  High                            337 (98.3)       909 (89)                                   
  Surgery                                                                                     .0001
  No surgery                      16 (3.2)         92 (4.6)         0.0724                    
  TURBT                           233 (46.7)       1115 (55.9)      0.1842                    
  Partial cystectomy              9 (1.8)          30 (1.5)         0.0236                    
  Radical cystectomy              97 (19.4)        336 (16.8)       0.0677                    
  Pelvic exenteration             86 (17.2)        201 (10.1)       0.2098                    
  Other                           57 (11.4)        218 (10.9)       0.0159                    
  Unknown procedure               1 (0.2)          4 (0.2)          0                         
  Lymph nodes removed                                               0.2643                    \<.0001
  None                            306 (61.3)       1469 (73.6)                                
  More than one                   193 (38.7)       527 (26.4)                                 
  Radiation                                                                                   .1759
  Beam radiation                  58 (11.6)        183 (9.2)        0.0805                    
  Radiation unknown               0 (0)            3 (0.2)          0.0549                    
  Performance unknown             441 (88.4)       1810 (90.7)      0.0753                    
  Cancer‐specific mortality                                                                   .0625
  Alive                           353 (70.7)       1496 (74.9)      0.0947                    
  Dead                            146 (29.3)       500 (25.1)                                 
  Overall mortality                                                 0.0411                    .4400
  Alive                           256 (51.3)       1065 (53.4)                                
  Dead                            243 (48.7)       931 (46.6)                                 

Abbreviations: MPUC, micropapillary urothelial carcinoma; NOS, not otherwise specified; TCC, transitional cell carcinoma; TURBT, transurethral resection of bladder tumor.
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3.3. Subgroup analyses {#cam43147-sec-0013}
----------------------

The subgroup analytical results are shown in Figure [2](#cam43147-fig-0002){ref-type="fig"}. After adjusting for potential covariates, the tests for interaction were not statistically significant for sex, age, T stage, and N stage in terms of both OM and CSM. This indicated that MPUC had a worse prognosis in all groups except for distal metastasis. Only MPUC patients without distal metastasis faced a higher risk of CSM (HR = 1.33, 95% CI = 1.10‐1.61, *P* \< .0001). However, in the OM analysis, the *P* value of N stage in the test for interaction was .0521 and near .05. This might have resulted from a relatively insufficient sample size or lymph node metastasis might interact with MPUC histology.

![Subgroup analysis for interaction between micropapillary urothelial carcinoma and potential covariates in both overall mortality and cancer‐specific mortality](CAM4-9-4897-g002){#cam43147-fig-0002}

4. DISCUSSION {#cam43147-sec-0014}
=============

In this study, we aimed to investigate prognostic values of clinicopathological characteristics and survival outcomes in MPUC of the urinary bladder. Given that TCC accounts for approximately 95% of bladder cancers, MPUC, and TCC were compared using records from the SEER database according to specified inclusion criteria. Micropapillary urothelial carcinoma and TCC had different effects on patients\' OM, especially the 5‐year survival status (*P* \< .0001). Moreover, patients with MPUC were at a higher risk of OM (HR = 1.39, 95% CI = 1.22‐1.57, *P* \< .0001), but their CSM (HR = 1.18, 95% CI = 1.00‐1.40, *P* = .0505) was fair. This indicated that MPUC could be an independent prognostic factor for OM in patients with urinary bladder cancer. Furthermore, in the subgroup analysis, only MPUC patients without distal metastasis faced a higher risk of CSM (HR = 1.33, 95% CI = 1.10‐1.61, *P* \< .0001).

This study supported previous research that reported that MPUC could be an independent prognostic factor for OM (HR = 1.39, 95% CI = 1.22‐1.57, *P* \< .0001). However, in terms of CSM, MPUC as a prognostic factor is still controversial because the *P* value for both the adjusted model II (.0505) and the PSM adjusted model (.0469) are near .05 in different sides. Sui et al analyzed 869 MPUC patients from the National Cancer Database (2004‐2014) and suggested that MPUC independently predicted a decreased OM, but they did not analyze CSM.[^8^](#cam43147-bib-0008){ref-type="ref"} Vourganti et al enrolled 120 MPBC patients from the SEER database (2001‐2008) and found no survival difference between MPUC and UC after controlling for stage and grade.[^11^](#cam43147-bib-0011){ref-type="ref"} A multi‐institutional analysis based on 151 MPUC patients demonstrated that MPUC was not independently associated with the risks of recurrence or OM.[^9^](#cam43147-bib-0009){ref-type="ref"} Although Abufaraj et al included 15 studies in their meta‐analysis, their results focused on patients undergoing RC or neoadjuvant chemotherapy.[^10^](#cam43147-bib-0010){ref-type="ref"} Compared with the above studies, the present study analyzed a sufficient number of patients and adjusted covariates to consider overall survival. Briefly, this study indicated that MPUC is an independent prognostic factor for OM at the population level. Interestingly, in the subgroup analysis of this study, MPUC patients without distal metastasis faced a higher risk of CSM (HR = 1.33, 95% CI = 1.10‐1.61, *P* \< .0001), even though CSM, as an independent prognostic factor, remains controversial. This finding indicated that M0 MPUC patients may require aggressive treatments to improve CSM.

Most MPUC cases in this study were diagnosed with muscle invasive bladder cancer (MIBC) compared with TCC cases (63.39% vs 9.39%, *P* \< .001), and MPUC patients had higher rates of lymph node metastasis (24.28% vs 1.32%, *P* \< .001) and distal metastasis (10.79% vs 1.17%, *P* \< .001). Higher‐grade disease was also more common in the MPUC group (97.49% vs 49.38%, *P* \< .001). These aggressive pathologic features have also been noted in other studies.[^8^](#cam43147-bib-0008){ref-type="ref"}, [^9^](#cam43147-bib-0009){ref-type="ref"}, [^12^](#cam43147-bib-0012){ref-type="ref"} According to another study, even if MPUC constituted less than 10% of a UC, the patients had worse prognoses.[^13^](#cam43147-bib-0013){ref-type="ref"} Micropapillary urothelial carcinoma contains small, tight clusters of high‐grade or infiltrating tumor cells,[^5^](#cam43147-bib-0005){ref-type="ref"} and its morphological characteristics are related directly to molecular alterations.[^6^](#cam43147-bib-0006){ref-type="ref"} Conventional TCC may be categorized broadly into the luminal and basal types, but MPUC tends to be luminal with expression of markers such as FOXA1 and GATA3.[^14^](#cam43147-bib-0014){ref-type="ref"} Moreover, human epidermal growth factor receptor 2 overexpression and amplification are common in MPUC,[^7^](#cam43147-bib-0007){ref-type="ref"}, [^15^](#cam43147-bib-0015){ref-type="ref"} which can also be characterized by activation of the miR‐296 and RUVBL1 target genes.[^5^](#cam43147-bib-0005){ref-type="ref"} Furthermore, epithelial membrane antigen and E‐cadherin participate in MPUC polarity reversal.[^16^](#cam43147-bib-0016){ref-type="ref"} These molecular mechanisms might be helpful for early diagnosis and further treatment of this cancer.

In this study, the most common surgery type in the MPUC group was TURBT (47.01%, 244/519), followed by RC (19.27%, 100/519) and pelvic exenteration (17.34%, 90/519). In addition, MPUC patients had more lymph nodes removed (38.54% vs 4.24%, *P* \< .001) and were more likely to be treated with beam radiation (11.18% vs 2.00%, *P* \< .001) than patients in the TCC group. Given that 63.39% of MPUC patients have MIBC, the treatment is relatively conservative and may be responsible for worse prognoses. Although RC was recommended in MIBC guidelines, early RC in non‐MIBC patients is still controversial.[^10^](#cam43147-bib-0010){ref-type="ref"} A population‐based study showed no difference between RC and bladder preservation surgery for cT1 MPUC,[^8^](#cam43147-bib-0008){ref-type="ref"} while Willis et al reported a better prognosis after early RC.[^17^](#cam43147-bib-0017){ref-type="ref"} Cisplatin‐based neoadjuvant therapy was commonly given to improve MIBC prognoses, but it is unclear whether it actually does. Sui et al found no survival benefit from MPUC after neoadjuvant chemotherapy.[^8^](#cam43147-bib-0008){ref-type="ref"} Although other studies reported pathological downstaging, this does not translate into better survival outcomes.[^18^](#cam43147-bib-0018){ref-type="ref"} In this study, MPUC was found to be an independent prognostic factor for OM and for CSM in the M0 subgroup. We suggest that, once MPUC components are found by biopsy, an advanced combined treatment should be considered. However, multicenter clinical trials are needed to establish a better therapeutic protocol for this rare, but aggressive, cancer.

This study had several strengths. First, we enrolled 519 patients with MPUC of the urinary bladder from 2004 to 2016; thus, we had a sufficient sample size to perform an exact and multiform analysis. Subgroup analyses and PSM were used to analyze potential confounding factors. Second, we updated clinicopathological characteristics and survival outcomes of MPUC, based on recent data. However, our study also had some limitations. First, this study had instinct limitations due to its retrospective nature. Selection bias may exist, which is inevitable for clinical observational studies, even those using PSM. Second, the SEER database lacked some essential variables; for example, treatment regimens were classified into two major categories as either surgery or radiotherapy, but chemotherapy and new therapies such as checkpoint‐inhibitor drugs were absent; including these treatment modalities might have led to different outcomes.

5. CONCLUSIONS {#cam43147-sec-0015}
==============

The prognosis of MPUC is poorer than that of TCC. Micropapillary urothelial carcinoma is an independent prognostic factor for OM in patients with urinary bladder cancer. In the subgroup analysis, only MPUC patients without distal metastasis faced a higher risk of CSM.
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